CN1460520A - Compound alliin enteric solubility capsule - Google Patents
Compound alliin enteric solubility capsule Download PDFInfo
- Publication number
- CN1460520A CN1460520A CN 03123854 CN03123854A CN1460520A CN 1460520 A CN1460520 A CN 1460520A CN 03123854 CN03123854 CN 03123854 CN 03123854 A CN03123854 A CN 03123854A CN 1460520 A CN1460520 A CN 1460520A
- Authority
- CN
- China
- Prior art keywords
- alliin
- allinase
- enteric coated
- buffer agent
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The compound alliin enteric soluble capsule in which the alliin and alliinase are sealed, and the weight mixing ratio of alliin and alliinase is 2.5:1.0 to 0.7:1.0, and the enteric soluble capsule also contains inhibitor and buffer agent, said inhibitor content is 0.6%-1.5% of total weight of alliin and alliinase, and the buffer agent content is 0.6%-1.5% of total weight of alliin and alliinase. Said capsule is stable and safe, and has the therapeutic effects of resisting thrombosis, reducing blood fat, preventing and curing cardio-cerebrovascular diseases, resisting tumor, resisting fungi and resisting SARS virus.
Description
Technical field
The present invention relates to medical drugs, is a kind of compound recipe alliin enteric coated capsule, and it has control cardiovascular and cerebrovascular disease, antitumor, antifungal and antiviral effect.
Background technology
Bulbus Allii has another name called giant garlic, for the underground bulb of Liliaceae allium Bulbus Allii (Allium sativum L.), is time-honored medicine food dual purpose plant, studies have shown that in a large number, and it has blood fat reducing, antithrombotic, sterilization, effect such as anticancer.But at present the content of the bright Bulbus Allii of domestic and international market or crude preparation by using (Bulbus Allii powder sheet or Bulbus Allii oil capsule etc.) alliin and allinase is low, thus its curative effect a little less than, do not cause and use clinically.
One, the present inventor has proposed the Chinese patent application of " extracting the method for alliin from Bulbus Allii ", and its number of patent application is 00101244.4, and its publication number is CN1273969A.
Two, the present inventor has finished the invention of " extracting the alliin production technology from bright Bulbus Allii ", and this invention has proposed Chinese patent application, and its number of patent application is 03100420.2.
Three, the present inventor has finished the invention of " extracting the allinase production technology from bright Bulbus Allii ", and this invention has proposed Chinese patent application, and its number of patent application is 03100419.9.
Summary of the invention
The invention provides a kind of compound recipe alliin enteric coated capsule, it has control cardiovascular and cerebrovascular disease, antitumor, antifungal and antiviral effect.
Technical scheme of the present invention is achieved like this: a kind of compound recipe alliin enteric coated capsule, comprise enteric coated capsule, alliin and allinase are housed in this enteric coated capsule and are sealed in the capsule, and alliin is 2.5 to 1.0 to 0.7 to 1.0 with the weight proportion of allinase, also contain inhibitor and buffer agent in this enteric coated capsule, the content of this inhibitor is 0.6 to 1.5% of alliin and allinase gross weight, this inhibitor is a sodium chloride, and the content of this buffer agent is 0.6 to 1.5% of alliin and allinase gross weight.
Above-mentioned alliin also can be 2.0 to 1.0 to 0.7 to 1.0 with the weight proportion of allinase.
Above-mentioned buffer agent is citric acid buffer agent or borate buffer or acetate buffer agent or phosphoric acid buffer agent.
Compound recipe alliin enteric coated capsule of the present invention has characteristics stable and safety, and has following drug effect: 1, owing to have anti thrombotic action and effect for reducing blood fat, thereby have the effect of control cardiovascular and cerebrovascular disease; 2, has antitumor action; 3, have antifungal and antiviral effect.
Description of drawings
Accompanying drawing 1 is the infrared absorpting light spectra of the embodiment products obtained therefrom in " extracting the alliin production technology from bright Bulbus Allii " patent application document;
Accompanying drawing 2 is the infrared absorpting light spectra of the standard reference material (alliin) in " extracting the alliin production technology from bright Bulbus Allii " patent application document;
Accompanying drawing 3 is embodiment gained alliin efficient liquid phase chromatographic analysis (the being HPLC) collection of illustrative plates (1-Alliin, 2-acetanilide) in " extracting the alliin production technology from bright Bulbus Allii " patent application document.
Accompanying drawing 4 is allinase (A, B), standard protein (C, 3mg/mL) electrophoretogram in " extracting the allinase production technology from bright Bulbus Allii " patent application document;
Accompanying drawing 5 is substrate (alliin) and product (acetone acid, allicin) efficient liquid phase chromatographic analysis (being HPLC) chromatogram in " extracting the allinase production technology from bright Bulbus Allii " patent application document;
Accompanying drawing 6 is the allinase catalysis alliin polymerization kinetics curves in " extracting the allinase production technology from bright Bulbus Allii " patent application document.
The specific embodiment
The present invention is not subjected to the restriction of following embodiment, can determine concrete embodiment according to the technical scheme and the practical situation of the invention described above.
Embodiment 3, this compound recipe alliin enteric coated capsule, comprise enteric coated capsule, alliin and allinase are housed in this enteric coated capsule and are sealed in the capsule, and alliin is 0.9 to 1.0 with the weight proportion of allinase, also contains inhibitor and buffer agent in this enteric coated capsule, and the content of this inhibitor is 0.6% or 1.0% or 1.5% of alliin and allinase gross weight, this inhibitor is a sodium chloride, and the content of this buffer agent is 0.6% or 1.0% or 1.5% of alliin and allinase gross weight; Alliin conversion ratio through this compound recipe alliin enteric coated capsule of measuring is 95.1.
Embodiment 4, this compound recipe alliin enteric coated capsule, comprise enteric coated capsule, alliin and allinase are housed in this enteric coated capsule and are sealed in the capsule, and alliin is 0.7 to 1.0 with the weight proportion of allinase, also contains inhibitor and buffer agent in this enteric coated capsule, and the content of this inhibitor is 0.6% or 1.0% or 1.5% of alliin and allinase gross weight, this inhibitor is a sodium chloride, and the content of this buffer agent is 0.6% or 1.0% or 1.5% of alliin and allinase gross weight; Alliin conversion ratio through this compound recipe alliin enteric coated capsule of measuring is 97.4.
In embodiment 1 to 4, buffer agent can be citric acid buffer agent or borate buffer or acetate buffer agent or phosphoric acid buffer agent.
Alliin conversion ratio measuring method at the compound recipe alliin enteric coated capsule described in the embodiment 1 to 4 is: at first alliin in the compound recipe alliin enteric coated capsule and allinase are mixed ultrasonic 30 seconds, in 15 fens kinds of 35 ℃ of water bath heat preservations with suitable quantity of water; Secondly draw 2 milliliters of reactions, and add 3 milliliters of methanol, mixing; Use microporous filter membrane (0.45 μ m) to filter then, filtrate HPLC sample introduction obtains chromatogram, calculates the alliin reduction, thereby calculates the alliin conversion ratio.
In the present invention, the technology that is sealed in alliin and allinase in the capsule to be adopted all is known or public routine techniques at present.
Compound recipe alliin capsule of the present invention proves through the overstability accelerated test: this compound recipe alliin capsule is to humidity and responsive to temperature, dry under terms of packing, can preserve 24 months below 4 ℃, the variation of alliin content, allinase vigor and allicin burst size is all less than 10%.
The capsular pharmacodynamics test of compound recipe alliin of the present invention:
1, anti thrombotic action: " the chemical compound biological activity test report of The National Center for Drug Screening of Shanghai Pharmaceutical Inst., Chinese Academy of Sciences " screening model: platelet aggregation algoscopy.The result: on average assembling suppression ratio during " compound recipe alliin " concentration 25,50,75 μ g/ml is 12,23,49%.
25.0,6.25 the anti thrombotic action result of the test of institute of materia medica, Xinjiang shows: " alliin ", " allinase " reach " compound recipe alliin " oral administration or intravenously administrable, and each dosage group (large, medium and small dosage is respectively:, 1.56mg/Kg) all has inhibitory action in various degree to rats in vitro " thrombosis ".Suppression ratio is 20.0～55.0%; And be obvious enhancing trend with its inhibitory action of increase of dosage; Each dosage group and N.S compare simultaneously, the equal tool statistical significance of difference, P＜0.01.Wherein the vena femoralis injection administration is stronger to the thrombosis inhibitory action than oral.Its low dose of thrombosis effect suppression ratio of allinase intravenously administrable is 54.0%.Oral administration wherein dosage thrombosis suppression ratio is 54.92%.
3.12,6.25 2, effect for reducing blood fat: the anti thrombotic action result of the test of institute of materia medica, Xinjiang shows: " alliin ", " allinase " reach " compound recipe alliin " oral administration or intravenously administrable, and large, medium and small three dosage groups (be respectively:, 12.5mg/Kg) all can obviously reduce the level of cholesterol in serum (Cho), triglyceride (TRI).Each dosage group also has regulating action to high density lipoprotein (HDL) and low density lipoprotein, LDL (LDL) simultaneously.But have only " compound recipe alliin " each dosage group to rat blood serum HDL level and wherein, small dose group is to the influence and high blood lipid model group comparing difference tool statistical significance (P＜0.01 or P＜0.05 of rat blood serum LDL level.
3, antitumor action: " The National Center for Drug Screening of Shanghai Pharmaceutical Inst., Chinese Academy of Sciences chemical compound test report " anti-tumor biological body outer screening test: test sample: " alliin ", " allinase " reach " compound recipe alliin (alliin+allinase) ".Screening technique: sulphonyl rhodamine protein staining method, tetrazolium reducing process.Action time: 48～72 hours.The result shows: " compound recipe alliin " reaches " allinase " has extracorporeal anti-tumor function to A-549 people's gland lung carcinoma cell and P-388 mouse leukemia cell.And " compound recipe alliin " has potent to the P-388 mouse leukemia cell.
4, antifungic action: The National Center for Drug Screening of Shanghai Pharmaceutical Inst., Chinese Academy of Sciences chemical compound biological activity (antifungal) test report: the trace liquid diluting method is measured minimum inhibitory concentration (MIC)≤20 μ g/ml of compound recipe alliin to saccharomyces albicans.Be judged as effectively.
The institute of materia medica, Xinjiang: " alliin ", " allinase " reach " compound recipe alliin " external antifungal result of the test and show: alliin has significantly anti-candida albicans effect, its minimum inhibitory concentration (MIC), half Mlc (MIC
50) and 90% Mlc (MBC
90) be respectively 1000 μ g/ml, 250 μ g/ml, 500 μ g/ml; The compound recipe alliin all has in various degree antibacterial, bactericidal action to each strain subject; But allinase is not seen antifungic action.
The institute of materia medica, Xinjiang: " alliin ", " allinase " reach the interior antifungal result of the test of " compound recipe alliin " body and show: alliin has tangible anti-candida albicans effect, to the median effective dose (ED of this bacterium infecting mouse
50) be 31.98mg/Kg; Compound recipe alliin anti-candida albicans ED
50Be 81.26mg/Kg.
5, antivirus action: The National Center for Drug Screening of Shanghai Pharmaceutical Inst., Chinese Academy of Sciences carries out antiviral drug effect research test, and The selection result is positive.
The source of alliin and allinase is described below:
One, used alliin can be that sell in market among the present invention, also can adopt propose with the inventor of present patent application, number of patent application be 00101244.4, denomination of invention is the alliin of the invention gained of " extracting the method for alliin from Bulbus Allii ", also can adopt with inventor's invention of present patent application, number of patent application be 03100420.2, denomination of invention is the alliin of the invention gained of " extraction alliin production technology from bright Bulbus Allii ".
Number of patent application be 03100420.2, denomination of invention is the invention of " extract alliin production technology " from bright Bulbus Allii, its technical scheme is achieved like this:
A kind of alliin production technology of from bright Bulbus Allii, extracting, carry out according to the following steps:
The first step is carried out pretreatment: garlic clove is carried out microwave enzyme killing handles, make garlic clove from white become translucent till;
Second step carried out Organic substance and extracts: the garlic clove after the microwave treatment is worn into 100 to 200 purpose Bulbus Alliis slurry, and adding ethanol, be 40% to 70% with ethanol gravimeter control Bulbus Allii slurry concentration of alcohol, stirred 2 to 10 hours, separate obtaining extracting solution, and the concentrating under reduced pressure extracting solution;
The 3rd step was used the alliin in the cationic exchange resin adsorption concentrated extracting solution: concentrated extracting solution is passed through the cationic exchange resin adsorption post;
The 4th step was used ammonia desorbing alliin: with 2.0 to 0.4 moles of ammonia water elution cationic exchange resin adsorption posts, the collection pH value is the eluent in 5.0 to 9.0 scopes;
The 5th step obtained crystalline alliin: the concentrating under reduced pressure eluent, and press 20% to 35% of concentrate eluant volume and add ethanol, and be in 5.5 to 6.5 scopes with hydrochloric acid or ammonia adjusting pH value, room temperature left standstill 24 to 60 hours, separated out crystalline alliin.
In above-mentioned pretreatment: garlic clove can be placed microwave 2 to 5 minutes.
Above-mentioned microwave frequency can be 2540 ± 50MHz, and the output microwave power can be 20KW.
In above-mentioned concentrating under reduced pressure, concentrating under reduced pressure can adopt multiple-effect decompression thin film concentration method to carry out, the end outlet temperature be controlled in 40 to 60 ℃ of scopes or 70 to 90 ℃ of scopes in, the ratio of the liquid volume after concentrating and the weight of the bright Bulbus Allii of raw material is controlled in 0.8 to 1.2 or 0.4 to 0.6 or 1/45 to 1/55 the scope.
In concentrated extracting solution, add 1 to 6% clarifier and stir, in temperature is-5 to 5 ℃ of scopes, place and obtain supernatant after 5 to 20 hours, and supernatant is carried out passing through the cationic exchange resin adsorption post behind the concentrating under reduced pressure, wherein clarifier is a fruit juice clarifier.
After the cationic exchange resin adsorption post is saturated, can wash adsorption column with distilled water earlier, and wash that to be Molish reaction negative or distilled water consumption to effluent be 0.5 to 1.5 times of garlic clove weight, and then with ammonia eluting cationic exchange resin adsorption post.
After above-mentioned crystalline alliin is lower than 2.9% through drying under reduced pressure to the water content in 60 to 80 ℃ of scopes, carry out airtight preservation with nitrogen or noble gas.
Above-mentioned separation device therefor can adopt freezing closed screenings self-separation fiberizer or centrifugal swing dryer or low temperature tubular type centrifugal separator; Or/and above-mentioned cationic exchange resin adsorption post can adopt styrene group strongly acidic cation exchange resin adsorption column or 732 type strong-acid cation-exchange resin adsorption columns or 850 type strong-acid cation-exchange resin adsorption columns or 800 type macroporous type strong acid sun resin absorption post.
It is the medicinal alliin of raw material mass production that the invention of above-mentioned relevant alliin is suitable for bright Bulbus Allii.Do ultraviolet spectra and infrared spectrum contrast with above-mentioned invention products obtained therefrom about alliin through fusing point test and standard reference material, every index confirms that product is an alliin.Through efficient liquid phase chromatographic analysis, the invention gained alliin product yield of above-mentioned relevant alliin is 1.0 ‰ ± 10%, and containing alliin is 91.2 ± 2%.
The invention of above-mentioned relevant alliin is not subjected to the restriction of following embodiment, can determine concrete embodiment according to the technical scheme and the practical situation of above-mentioned invention about alliin.
The inventive embodiment of above-mentioned relevant alliin, undertaken by following step:
The first step is carried out pretreatment: garlic clove is carried out microwave enzyme killing handles, make garlic clove from white become translucent till; Preferably garlic clove was placed microwave 2 minutes or 3.5 minutes or 5 minutes, and microwave frequency is preferably 2540 ± 50MHz, the output microwave power is preferably 20KW.Carrying out before microwave enzyme killing handles, preferably the garlic clove demoulding is being cleaned and drained.
Second step carried out Organic substance and extracts: the garlic clove after the microwave treatment is worn into 100 to 200 purpose Bulbus Alliis slurry, and add ethanol or ethanol, and be 40% to 70% with ethanol gravimeter control Bulbus Allii slurry concentration of alcohol, stirring reaction 2 to 10 hours, separate obtaining extracting solution, and the concentrating under reduced pressure extracting solution.Preferably weight is extracted 3 times or 5 times again.Concentrating under reduced pressure preferably adopts multiple-effect decompression thin film concentration method to carry out, the end outlet temperature is controlled in 40 to 60 ℃ of scopes, recovered solvent is that ethanol is reusable, and the ratio of the extracting liquid volume after concentrating and the weight of the bright Bulbus Allii of raw material is controlled in 0.8 to 1.2 the scope.Before adsorbing with the cationic exchange resin adsorption post, be preferably in the concentrated extracting solution and add 1% or 3% or 6% clarifier and stir, in temperature is-5 to 5 ℃ of scopes, place and obtain supernatant after 5 hours or 10 hours or 20 hours, and supernatant carried out adsorbing by the cationic exchange resin adsorption post behind the concentrating under reduced pressure, wherein clarifier is the fruit juice clarifier of selling on the market, as: can select the outstanding board 101 type fruit juice clarifiers of the Chinese of selling on the market for use, the ratio that supernatant carries out the weight of the bright Bulbus Allii of volume and raw material behind the concentrating under reduced pressure is controlled in 0.4 to 0.6 the scope, the end outlet temperature is controlled in 40 to 60 ℃ of scopes, and recovered solvent is that ethanol is reusable.
The 3rd step was used the alliin in the cationic exchange resin adsorption concentrated extracting solution: concentrated extracting solution or concentrated supernatant are passed through the cationic exchange resin adsorption post.After the cationic exchange resin adsorption post is saturated, preferably with distilled water adsorption column is washed earlier, and wash to effluent and be the Molish reaction negative or the distilled water consumption is 0.5 times or 1.5 times of garlic clove weight, and then carry out the following step and promptly use ammonia desorbing alliin.
The 4th step was used ammonia desorbing alliin: with the ammonia eluting cationic exchange resin adsorption post in 2.0 to 0.4 molar range, the collection pH value is the eluent in 5.0 to 9.0 scopes;
The 5th step obtained crystalline alliin: the concentrating under reduced pressure eluent, wherein concentrating under reduced pressure is or/and solvent recovery preferably adopts multiple-effect thin film concentration method to carry out, the end outlet temperature is controlled in 70 ℃ or 90 ℃ or 70 to the 90 ℃ of scopes, the ratio of the liquid volume after concentrating and the weight of the bright Bulbus Allii of raw material is controlled in 1/45 to 1/55 the scope, recovered solvent is that ammonia is reusable, press 20% or 35% of concentrate eluant volume then and add ethanol, and to regulate pH value with hydrochloric acid or ammonia be in 5.5 to 6.5 scopes, room temperature left standstill 24 hours or 50 hours or 60 hours, separated out crystalline alliin.After preferably crystalline alliin being lower than 2.9% through drying under reduced pressure to the water content in 60 to 80 ℃ of scopes, carry out airtight preservation with nitrogen or noble gas.
In the above-described embodiments: separate device therefor and preferably adopt freezing closed screenings self-separation fiberizer or centrifugal swing dryer or low temperature tubular type centrifugal separator; The cationic exchange resin adsorption post can adopt styrene group strongly acidic cation exchange resin adsorption column or 732 type strong-acid cation-exchange resin adsorption columns or 850 type strong-acid cation-exchange resin adsorption columns or 800 type macroporous type strong acid sun resin absorption post.
Be to be the affirmation of alliin to the foregoing description products obtained therefrom below:
Standard reference material: Alliin-S (Indofine Chemical Company Inc.USA, purity 99.5%, lot number: 97112003)
1, character
Above-mentioned alliin product is a white crystalline powder.Very easily water-soluble.Be insoluble to ethanol, chloroform.Microscopically is viewed as colourless acicular crystal.It is pH=5.7-6.2 that the polyacrylamide gel isoelectric focusing electrophoresis calculates isoelectric point, IP.Conform to standard reference material.
2, fusing point
Measure fusing point according to 2000 editions two appendix VIC melting point determinations of Chinese Pharmacopoeia, first method, the standard reference material fusing point is 164-166 ℃ (decomposition).The said goods fusing point is 162-165 ℃ (decomposition).2 ℃ in advance of above-mentioned alliin product fusing points, molten distance has expansion slightly, shows that product purity is not as good as standard reference material.
3, ultra-violet absorption spectrum confirms that the said goods is an alliin, the suitable standard reference material 93.7% of estimation product alliin content
Alliin standard reference material (Alliin-S) is the solution that solvent is made 42 μ g/ml with methanol, dilutes 7 times.Record ultraviolet spectra with S-50 type ultraviolet spectrophotometer (Shanghai rib light), absorption maximum is arranged at 226 ± 1nm place.Trap is 0.380, E
1% 226 ± 1nm=90.5.The said goods (Alliin-D) is that solvent is made 40 μ g/ml solution with methanol, dilutes 7 times, measures ultraviolet spectra under same instrument similarity condition, at 226 ± 1nm place absorption maximum is arranged.Trap is 0.339.E
1％ 226±1nm＝84.8
Both ultra-violet absorption spectrums are identical.With E
1% 226 ± 1nm(Alliin-D) and E
1% 226 ± 1nm(Alliin-S) calculate alliin content.84.8/90.5 * 100=93.7, the said goods contain 93.7% of the suitable standard reference material of alliin.
4, infrared absorption spectroscopy
Alliin standard reference material and the said goods are at EQUINOX55, and BRUKER infrared spectrophotometer-ATR adnexa is measured infrared absorption spectroscopy.The said goods collection of illustrative plates (accompanying drawing 1) is consistent with standard reference material collection of illustrative plates (accompanying drawing 2).But 1533,1526cm
-1Small and weak peak appears at the place.1050-1430cm at finger print region
-1Section has nuance.Illustrate that product contains small amount of impurities.
5, conclusion
The result's judgement and the affirmation embodiment products obtained therefrom that obtain according to character examination, fusing point test, ultra-violet absorption spectrum and infrared absorption spectrum analysis are alliin.
Below the foregoing description products obtained therefrom is measured its alliin content:
Measure alliin content in the present embodiment products obtained therefrom with efficient liquid phase chromatographic analysis (being HPLC).
1, test liquid preparation
Alliin standard reference material and embodiment products obtained therefrom add interior mark (acetanilide) respectively, are configured to test liquid with mobile phase.(content: the about 100.0 μ g/ml of alliin, acetanilide 10.0 μ g/ml).
2, chromatographic condition
Agilent 1100 high performance liquid chromatographs, ZORBAX SB-C
18Post (4.6 * 250mm, 5.0 μ m); Mobile phase: methanol-water (60: 40); Flow velocity 0.8ml/min; Detect wavelength 214nm; Column temperature: 37 ℃.Interior mark: acetanilide.Test liquid sample size: 10 μ l.Obtain chromatogram (accompanying drawing 3), retention time: alliin 3.07 minutes, acetanilide 5.12 minutes.Separating degree (R)=14.6, theoretical cam curve (n)=7.4 * 10
3Sheet.
3, linearity and regression equation
Sample size in 0.5-3.0 μ g scope, with peak area to concentration map regression equation: Y=10.3X-9.8, r=0.9993.
Withinday precision RSD=i.88% (n=5).Day to day precision RSD=2.65% (n=5).
4, the content of three batches of products of embodiment gained
Three batches of products of embodiment gained (lot number: A, B, C), through efficient liquid phase chromatographic analysis (being HPLC), three batches of product yields are 1.0 ‰ ± 10%, contain alliin 91.2 ± 2%.
5, determination of foreign matter
The three batches of products are according to Chinese Pharmacopoeia 2000 editions two appendix chlorides, iron salt, sulfate, ammonium salts are lower than, moisture, ash are checked method check.The result is: chloride, iron salt, sulfate are lower than 0.01%.Ammonium salt is lower than 0.02%.Moisture: 2.2-2.6%.Ash 0.07-0.11%.
Above-mentioned accompanying drawing 1 is the infrared absorpting light spectra of the foregoing description products obtained therefrom;
Above-mentioned accompanying drawing 2 is the infrared absorpting light spectra of above-mentioned standard reference material;
Above-mentioned accompanying drawing 3 is above-mentioned alliin efficient liquid phase chromatographic analysis (being HPLC) collection of illustrative plates (1-Alliin, 2-acetanilide).
Two, used allinase can be that sell in market among the present invention, also can adopt that inventor with present patent application proposes, number of patent application be 03100419.9, denomination of invention is the alliin of the invention gained of " extraction allinase production technology from bright Bulbus Allii ".
Number of patent application be 03100419.9, denomination of invention is the invention of " extract allinase production technology " from bright Bulbus Allii, its technical scheme is achieved like this: a kind of allinase production technology of from bright Bulbus Allii, extracting, carry out according to the following steps:
The first step adds the making beating of allinase extracting solution and isolates clear liquid: earlier the garlic clove temperature is controlled in-5 ℃ to the 5 ℃ scopes, and the control temperature is in-5 ℃ to 5 ℃ scopes, add the allinase extracting solution and wear into 100 to 200 purpose Bulbus Alliis slurry, the addition of allinase extracting solution is 0.8 to 1.2 times of garlic clove weight, and further isolates first clear liquid;
The second step fractional precipitation obtains allinase: the control temperature is in-5 ℃ to 5 ℃ scopes, under agitation ammonium sulfate is added in first clear liquid, make its whole dissolvings and control ammonium sulfate concentrations in 20% to 30% percent weight in volume concentration range, isolate second clear liquid then with the ammonium sulfate gravimeter; Under agitation ammonium sulfate is added in second clear liquid, make its whole dissolvings and control ammonium sulfate concentrations in 40% to 50% percent weight in volume concentration range, isolate the first pasty state precipitate then with the ammonium sulfate gravimeter; With the first pasty state precipitate polyurethane bag of packing into, dialysis is 30 hours to 50 hours in the frozen water dialysis groove in mobile-5 ℃ to 5 ℃ scopes, regulates with phosphoric acid then that to isolate the second pasty state precipitate behind the isoelectric pH to 4.9 be the pasty state allinase.
Said extracted liquid can be the aqueous solution that contains chelating agent, antioxidant, buffer agent and glycerol.
Above-mentioned chelating agent can be disodiumedetate; Above-mentioned antioxidant can be mercaprol; Above-mentioned buffer agent can be phosphate.
The allinase extracting solution can be in sodium hydrogen phosphate-potassium phosphate buffer to add by the buffer volume and adds 0.1% to 0.3% Na2EDTA, 0.02% to 0.06% mercaptoethanol, 0.3% to 1.0% sodium chloride, 5% to 15% glycerol.
In above-mentioned production technology, the second pasty state precipitate can be put into freezer dryer and carry out drying, make moisture be lower than 2.0%, obtain the lyophilizing allinase, carry out airtight preservation with nitrogen or noble gas then.
Above-mentioned separation device therefor can adopt freezing closed screenings self-separation fiberizer or centrifugal swing dryer or low temperature tubular type centrifugal separator.
It is the medicinal allinase of raw material mass production that the invention of above-mentioned relevant allinase is suitable for bright Bulbus Allii.The invention gained allinase product of above-mentioned relevant allinase proves that through the SDS-gel electrophoresis it has higher purity.According to (C: molecular weight 14400～97400) to calculate its allinase product list polymer molecular amount be 67000 dalton to Rf value with standard protein.Michaelis constant K
mBe 3.6mmol/L.The average vigor of its product is: 765U/g.
The invention of above-mentioned relevant allinase is not subjected to the restriction of following embodiment, can determine concrete embodiment according to the technical scheme and the practical situation of above-mentioned invention about allinase.
Embodiment, undertaken by following step:
The first step adds the making beating of allinase extracting solution and isolates clear liquid: earlier the garlic clove temperature is controlled in-5 ℃ to the 5 ℃ scopes, and the control temperature is in-5 ℃ to 5 ℃ scopes, add the allinase extracting solution and wear into 100 to 200 purpose Bulbus Alliis slurry, the addition of allinase extracting solution is 0.8 times or 1.2 times of garlic clove weight, and further isolates first clear liquid;
The second step fractional precipitation obtains allinase: the control temperature is in-5 ℃ to 5 ℃ scopes, under agitation ammonium sulfate is added in first clear liquid, make its whole dissolvings and control ammonium sulfate concentrations in 20% to 30% percent weight in volume concentration range, isolate second clear liquid then with the ammonium sulfate gravimeter; Under agitation ammonium sulfate is added in second clear liquid, make its whole dissolvings and control ammonium sulfate concentrations in 40% to 50% percent weight in volume concentration range, isolate the first pasty state precipitate then with the ammonium sulfate gravimeter; With the first pasty state precipitate polyurethane bag of packing into, dialysis is 30 hours to 50 hours in the frozen water dialysis groove in mobile-5 ℃ to 5 ℃ scopes, regulates with phosphoric acid then that to isolate the second pasty state precipitate behind the isoelectric pH to 4.9 be pasty state Bulbus Allii enzyme; The second pasty state precipitate is put into freezer dryer carry out drying, make moisture be lower than 2.0%, obtain the lyophilizing allinase, carry out airtight preservation with nitrogen or noble gas then.
In the above-described embodiments: extracting solution is the aqueous solution that contains chelating agent, antioxidant, buffer agent and glycerol; Chelating agent can be disodiumedetate; Antioxidant can be mercaprol; Buffer agent can be phosphate; The allinase extracting solution is preferably in sodium hydrogen phosphate-potassium phosphate buffer to add by the buffer volume and adds 0.1% or 0.3% Na2EDTA, 0.02% or 0.06% mercaptoethanol, 0.3% or 1.0% sodium chloride, 5% or 15% glycerol.
Separate device therefor and adopt freezing closed screenings self-separation fiberizer or centrifugal swing dryer or low temperature tubular type centrifugal separator.
Be to be the affirmation of allinase to the foregoing description products obtained therefrom below:
(1), sds gel electrophoresis is measured allinase product purity and molecular weight:
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) condition: adopt 10% separation gel, 4.5% concentrates glue making sheet.Point sample amount 20 μ L.CC type vertical electrophoresis groove, glycerol-tri methylol amino methane-HCl-dodecyl sodium sulfate buffer.Voltage 20mA electrophoresis launches, coomassie brilliant blue staining.The result shows a band.According to (C: molecular weight 14400～97400) Rf value gets regression equation: Y=-1.7297X+5.6399 (r=0.97) with standard protein.
Calculating the single polymer molecular amount of allinase sample (lot number: A:011105, B:020120) is 67000 dalton.As shown in Figure 4.
(2), the allinase vigor is tired:
Set up the method that HPLC measures substrate alliin, product allicin and acetone acid simultaneously.As shown in Figure 5.Allinase product 0.100g, purified water made dissolving in ultrasonic 30 seconds, made the 1.00mg/ml test liquid.With alliin (Indofine Chemical Company, Inc.USA content 99.5%.) make standard reference material.Hypersil-BDS-C
18Chromatographic column (4.6mm * 250mm, 5um), 35 ℃ of column temperatures, mobile phase: methanol-water (3: 2), flow rate: 0.8ml/min, 214nm detects.Sample size 10 μ l measure.Vigor with adjacent alliin and acetone acid chromatographic peak counting yield (allinase) is tired.Five batches of allinase products of embodiment gained catalysis activity average out to: 765U/g.
The enzyme amount (Ω) that 1 allinase unit of activity (U)=per minute cracking 1 μ mol alliin (substrate) needs.Five batches of average allinase vigor of allinase product are: 765U/g.
(3), enzyme kinetics curve and parameter
The allinase product adds substrate (alliin) and is made into test solution respectively.Ultrasonic mixing 30 seconds, 35 ℃ of water bath heat preservations.Respectively at 5,15,25min, and 1,3,5,7,9,11, that 13hr draws reactant liquor is an amount of, adds the methanol mixing.Cross 0.45 μ m filter membrane, HPLC sample introduction 10 μ l obtain chromatogram.Calculate alliin, acetone acid and allicin content.Draw the enzymatic reaction curve, as shown in Figure 6.
The characteristic reactions curve that shows allinase: 5 minutes is that the enzymatic reaction initial velocity (presents first order reaction: S+E → P with in.Its rate equation is :-d[S]/dt=k
1[S]); (presenting mixed class reacts: E+S ES → E+P to reach maximum reaction velocity in 25 minutes.)。Allicin concentration in time increases, and 15 minutes to its concentration of 13hr basicly stable (25 minutes-13hr is near zero order reaction).
Catalytic cracking reaction meets Michaelis-Menten equation: 1/V=0.129/[S]+0.0358.
Regression equation: Y=35.78+0.129X (r=0.996)
Maximum reaction velocity: V
Max=27.9molmin
-1Mg
-1
Michaelis constant: K
m=3.6mmol/L.
Above-mentioned accompanying drawing 4 is allinase (A, B), standard protein (C, 3mg/mL) electrophoretogram;
Above-mentioned accompanying drawing 5 is substrate (alliin) and product (acetone acid, allicin) efficient liquid phase chromatographic analysis (being HPLC) chromatogram;
Above-mentioned accompanying drawing 6 is an allinase catalysis alliin polymerization kinetics curves.
Claims (3)
1, a kind of compound recipe alliin enteric coated capsule, comprise enteric coated capsule, it is characterized in that alliin and allinase being housed in this enteric coated capsule and being sealed in the capsule, and alliin is 2.5 to 1.0 to 0.7 to 1.0 with the weight proportion of allinase, also contain inhibitor and buffer agent in this enteric coated capsule, the content of this inhibitor is 0.6 to 1.5% of alliin and allinase gross weight, and this inhibitor is a sodium chloride, and the content of this buffer agent is 0.6 to 1.5% of alliin and allinase gross weight.
2, compound recipe alliin enteric coated capsule according to claim 1 is characterized in that the alliin and the weight proportion of allinase are 2.0 to 1.0 to 0.7 to 1.0.
3, compound recipe alliin enteric coated capsule according to claim 1 and 2 is characterized in that buffer agent is citric acid buffer agent or borate buffer or acetate buffer agent or phosphoric acid buffer agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03123854 CN1231261C (en) | 2003-06-03 | 2003-06-03 | Compound alliin enteric solubility capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03123854 CN1231261C (en) | 2003-06-03 | 2003-06-03 | Compound alliin enteric solubility capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1460520A true CN1460520A (en) | 2003-12-10 |
| CN1231261C CN1231261C (en) | 2005-12-14 |
Family
ID=29591066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03123854 Expired - Fee Related CN1231261C (en) | 2003-06-03 | 2003-06-03 | Compound alliin enteric solubility capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1231261C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058878A (en) * | 2010-12-21 | 2011-05-18 | 中国药科大学 | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof |
| CN101549152B (en) * | 2009-02-13 | 2011-06-15 | 新疆埃乐欣药业有限公司 | Alliin/alliinase dualistic drug-releasing multilayer tablet |
| CN110554081A (en) * | 2019-10-17 | 2019-12-10 | 东莞太力生物工程有限公司 | Isoelectric point detection method of isoelectric focusing electrophoresis of recombinant protein |
-
2003
- 2003-06-03 CN CN 03123854 patent/CN1231261C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101549152B (en) * | 2009-02-13 | 2011-06-15 | 新疆埃乐欣药业有限公司 | Alliin/alliinase dualistic drug-releasing multilayer tablet |
| CN102058878A (en) * | 2010-12-21 | 2011-05-18 | 中国药科大学 | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof |
| CN102058878B (en) * | 2010-12-21 | 2013-04-10 | 中国药科大学 | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof |
| CN110554081A (en) * | 2019-10-17 | 2019-12-10 | 东莞太力生物工程有限公司 | Isoelectric point detection method of isoelectric focusing electrophoresis of recombinant protein |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1231261C (en) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1733130A (en) | Process for extracting litchi polyphenol from litchi | |
| CN104277134B (en) | A kind of preparation method and applications of the dictyophora fungus polysaccharide-chelates of zinc with anti-tumor activity | |
| CN1733754A (en) | Method for extracting persimmon polyphenol from persimmon | |
| CN1144803C (en) | Chinese chestnut flower flavone compound and its extraction process | |
| CN1129569C (en) | Cyclopentenone derivatives | |
| CN1231261C (en) | Compound alliin enteric solubility capsule | |
| CN1203057C (en) | Process for extracting alliin from fresh garlic | |
| CN1269527C (en) | Compound alliin powder injection | |
| CN1202067C (en) | Medicinal grade ferrum citricum iron-59 citrate and its preparation method | |
| CN1222613C (en) | Producing process for extracting allinase from garlic | |
| CN101032532A (en) | Medicine composition including active substrates extracted from Sang Huang, the preparing method and the application in the producing of medicine thereof | |
| CN1085674C (en) | Safflower total uranidin, its preparation and application | |
| CN1274309C (en) | Enteric-coated formulation of glycyrrhizic acid and its salt and its preparing method | |
| CN1840539A (en) | Salangane saponin and preparation method and use thereof | |
| CN1680290A (en) | Oximated ginger phenol and its synthesis and use | |
| CN1594332A (en) | Glycyrrhetic acid and phospholipid composites of glycyrrhetate and process for preparing same | |
| CN1218960C (en) | Ginkgo protein GAPIIa and its preparing method and use | |
| CN1887906A (en) | Hypoglycemic polypeptide from silkworm and its prepn and use | |
| CN1150027C (en) | Medicine for curing tumor and its preparation method | |
| CN1225262A (en) | Anti cancer drug contg. taxals alcohol | |
| CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof | |
| CN108059652A (en) | A kind of grifola frondosus selenium chelating peptide prepared using proteolytic cleavage | |
| CN108047310A (en) | A kind of grifola frondosus selenium chelating pentapeptide and preparation method thereof | |
| CN1361111A (en) | Furost saponine analogue and its separation process and use | |
| CN1217939C (en) | Compound of phycocyania of blue-green algae, its preparing method and usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: XINJIANG ELSON PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: BAOLIDA SCIENCE, INDUSTRIAL AND TRADE CO., LTD., XINJIANG |
|
| CP03 | Change of name, title or address |
Address after: 830011 No. 16, Henan East Road, the Xinjiang Uygur Autonomous Region, Urumqi, 1306 Patentee after: Xinjiang Ailexin Pharmaceutical Co., Ltd. Address before: 830026 No. 8 economic and Technological Development Zone, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: Baolida Science-Industry-Trade Co., Ltd., Xinjiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051214 Termination date: 20210603 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |